Question Bank › Conviction backed by things in hand

Conviction backed by things in hand

Conviction backed by things in hand: management stakes the next leg of growth on evidence it already possesses, not cond

Calls Tested
396
Answered YES
29
Hit Rate
7.3%
rare by design

Akoya Biosciences, Inc. (AKYA) — this company's answers

NO on the Q2 2023 call 2023-08-07 C+
The model's full reasoning — Q2 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否明确表达了对未来业务显著提升的信心,并且这种信心是否基于公司已经拥有的具体事物或已经发生的情况。 首先,寻找管理层关于未来业务提升的明确表述。在电话会议中,Brian McKelligon 和 Johnny Ek 多次提到增长、扩张、推动试剂收入等。例如,Brian 说:“我们专注于以下举措……继续提供新应用并推动工作流程和速度改进,以增加 PhenoCycler-Fusion 和 PhenoImager HT 的试剂拉动。” 他还提到:“我们预计并打算这一趋势继续,同时我们将内部投资集中在上游。” 此外,Johnny 提到:“我们重申2023年收入指导范围9500万至9800万美元,因为我们继续看到空间生物学市场的顺风。” 这些表明管理层对增长有信心,但需要看是否明确表示“业务将显著提升”而非“稳定持续”。 关于“显著提升”,管理层提到“强劲的第二季度”、“创纪录的收入”、“系统安装量创纪录”等,但关于未来,他们提到“继续强劲的顶线增长”、“推动试剂增长”等。他们并没有明确说“未来一年业务将显著提升”,而是强调持续增长和运营杠杆。例如,Brian 说:“我们专注于以下举措……推动系统利用率和试剂拉动。” 这更像是持续改进,而非“显著提升”。 其次,检查信心是否基于具体已拥有的东西。管理层提到了具体产品、升级、合作伙伴等。例如,Fusion 2.0 升级已开始,现场升级正在进行;PhenoCode 试剂面板已推出;与 CRO 网络合作;CLIA 实验室等。这些是已经存在或正在发生的事物。但管理层是否明确将这些与未来显著提升联系起来?他们提到“这些举措将推动系统利用率,减少样本到答案的时间,并增加仪器拉动。” 这暗示了增长,但并未明确说“业务将显著提升”。 此外,管理层提到“我们预计年试剂收入增长将在未来几年保持在这个范围”,这更像是稳定增长而非显著提升。他们还说“我们继续看到空间生物学市场的顺风”,这属于市场条件。 综合来看,管理层表达了对增长的信心,但并未明确说“业务将显著提升”,而是强调持续增长和运营改进。他们的信心基于具体产品、升级和合作伙伴,但这些是否构成“显著提升”的证据?可能更偏向于持续改进。 因此,我认为答案应为 NO,因为管理层没有明确表达“显著提升”的信念,而是强调持续增长和优化。同时,他们的证据是具体的,但并未明确连接到一个“显著提升”的表述。 最终答案:NO。

← Back to the full AKYA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that conviction in CONCRETE THINGS THE COMPANY ALREADY HAS IN HAND OR ALREADY HAPPENING — rather than in market conditions, industry recovery, or general optimism? Answer YES when BOTH halves come through together in management's own words, as one coherent posture, in whatever form fits the business: (1) STATED CONVICTION ABOUT A STEP-UP AHEAD. Management plainly conveys that it expects the business to be meaningfully bigger, busier, or stronger over roughly the coming year — not merely steady continuation, and not vague aspiration. The conviction should be unmistakable in how management talks about where the company is headed: confident, specific in direction, and owned by management itself. (2) THE CONVICTION RESTS ON EVIDENCE ALREADY IN THE COMPANY'S POSSESSION. When management explains WHY it is confident, it points to real, present-tense substance — in whatever form fits the industry — such as: business already won, signed, booked, or committed that has not yet fully shown up in results; work, orders, customers, or volumes already arriving or ramping now; a capability, capacity, product, or asset already built or in place that the growth will run through; observable customer behavior already occurring; or progress already made that management can describe concretely. The evidence should be specific enough that management is describing things that exist and can be pointed to, not projections, pipeline hopes, or a market thesis. Where analysts probe or doubt, management responds with this kind of already-real substance rather than with reassurance alone. Answer NO if management's confidence rests mainly on expected market recovery, industry tailwinds, macro improvement, pricing environments, seasonal patterns, or customer sentiment that has not yet converted into anything the company holds. NO if the forward talk is generic optimism, mission language, or big-market framing without concrete present-tense support. NO if the call conveys steady continuation, a defense of weak results, or a turnaround still promised rather than evidenced. NO if the evidence offered is only a raised financial guidance number, an analyst's model, or third-party forecasts. NO if the conviction and the evidence never connect — strong facts reported but no stated step-up ahead, or a stated step-up with nothing in hand behind it. NO if the posture appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
OEC Orion Engineered Carbons S.A. Q4 2022 2023-02-17 B+
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
CUE Cue Biopharma, Inc. Q3 2022 2022-11-14 D
ZVIA Zevia PBC Q1 2022 2022-05-12 B
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
LC LendingClub Corporation Q4 2021 2022-01-26 A
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
KTB Kontoor Brands, Inc. Q3 2021 2021-11-04 A
CMTL Comtech Telecommunications Corp. Q1 2019 2018-12-07 B+
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
ALB Albemarle Corporation Q3 2018 2018-11-08 B
WES Western Midstream Partners, LP Q3 2018 2018-10-31 D
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
INSM Insmed Incorporated Q4 2017 2018-02-23 B
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
FLEX Flex Ltd. Q1 2018 2017-07-28 F
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
ANIP ANI Pharmaceuticals, Inc. Q4 2016 2017-03-02 B+
GPOR Gulfport Energy Corporation Q4 2016 2017-02-14 A
WYY WidePoint Corporation Q3 2016 2016-11-09 D
LBTYK Liberty Global's Q1 2016 2016-05-10 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

CUE · Q3 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up to a meaningfully higher level, citing the recent $30M PIPE financing, Fast Track designation, emerging clinical data from CUE-101 monotherapy and combination trials, and the derisked Immuno-STAT platform as concrete assets already in hand that support advancing toward 2024 clinical development and potential registration paths. They ground this in present-tense facts such as the SITC data, cash runway extension, first CUE-102 patient dosed, and ongoing trial expansions rather than external market or industry conditions.
BFIN · Q1 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up: they have already achieved and exceeded the $40 million quarterly loan growth goal, are targeting $1.125–$1.150 billion in Q2 (with a reach to $1.2 billion by year-end), and expect EPS of $0. 14–$0.16 in Q2 rising $0.03–$0.05 per quarter thereafter, with ROE potentially in the 80s–90s run-rate by early 2023. This conviction rests on concrete, already-real evidence in hand: $45 million loan growth already booked in April 2022 (portfolio now over $1.
ALLY · Q1 2018 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction of a step-up: “we see these metrics meaningfully higher on a year-over-year basis, and that will fully continue over the medium term,” “adjusted EPS growth of 20% to 30% for the year,” “we expect net financing revenue to move higher,” “expect to see acceleration in this line item in Q2 and throughout the rest of 2018,” and “keeps us on the path to delivering our 2018 outlook.” That conviction is grounded in concrete, already-present items: record $9.

More from the question bank

Room to raise the ceilingSelling the shovels to a customer who just gStaircase quarter: best recent period just rCommitment step-up grounded in demand alreadCheap-to-serve incremental businessTheir own money is on the lineAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.